ACRX Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: The Motley Fool - Mentions: TLPH

Talphera Cuts Expenses 14 Percent

3 months ago - By: The Motley Fool - Mentions: TLPH

Talphera Cuts Costs and Speeds Trial

2 years ago - By: Seeking Alpha

AcelRx announces rebranding with name change to Talphera (NASDAQ:ACRX)

2 years ago - By: Talphera, Inc.

AcelRx Announces Rebranding With Name Change to Talphera, Inc.

2 years ago - By: Seeking Alpha

AcelRx Pharmaceuticals says CEO Angotti buys 10K shares in co (NASDAQ:ACRX)

2 years ago - By: Benzinga - Mentions: HSDT HSTO OGN ALLR

5 Value Stocks In The Healthcare Sector

2 years ago - By: Benzinga - Mentions: DVAX INVA OGN ALLR

Overview Of Value Stocks In The Healthcare Sector

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

2 years ago - By: InvestorPlace - Mentions: JTAI NXTP VIRC PSTX ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

2 years ago - By: Seeking Alpha

AcelRx Pharmaceuticals files for $150M mixed shelf (NASDAQ:ACRX)

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

2 years ago - By: Seeking Alpha

AcelRx CEO buys 10,000 shares (NASDAQ:ACRX)

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

2 years ago - By: AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

2 years ago - By: Seeking Alpha

AcelRx Pharmaceuticals launches ~$10M private placement of shares (NASDAQ:ACRX)

2 years ago - By: AcelRx Pharmaceuticals, Inc.

ACELRX PHARMACEUTICALS INC (ACRX) Stock News

ACRX Latest News, Press Relases and Analysis

Talphera Cuts Expenses 14 Percent

Talphera Cuts Costs and Speeds Trial

AcelRx announces rebranding with name change to Talphera (NASDAQ:ACRX)

AcelRx Announces Rebranding With Name Change to Talphera, Inc.

AcelRx Pharmaceuticals says CEO Angotti buys 10K shares in co (NASDAQ:ACRX)

5 Value Stocks In The Healthcare Sector

Overview Of Value Stocks In The Healthcare Sector

AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

AcelRx Pharmaceuticals files for $150M mixed shelf (NASDAQ:ACRX)

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

AcelRx CEO buys 10,000 shares (NASDAQ:ACRX)

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

AcelRx Pharmaceuticals launches ~$10M private placement of shares (NASDAQ:ACRX)

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules